
CLAIMS

What is claimed is:

1. A compound represented by Formula IA:




(IA);


or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

Lig is a monoclonal antibody;


L is selected from the group consisting of:




,







,



,












,






, , , and ;







wherein * denotes the point of attachment to R;

R is selected from the group consisting of:

, , , ,

, , , , ,

, , , ,

, , , , , and ;

wherein ** denotes the point of attachment to L; and


s is 0, 1, 2, 3, 4, 5, 6, 7, or 8.

2. The compound of claim 1, wherein Lig is selected from the group consisting of an anti-TROP2 antibody, an anti-EGRF antibody, an anti-HER2 antibody, an anti-B7-H3 antibody, an anti-CD30 antibody, an anti-CD33 antibody, and an anti-CD70 antibody.


3. The compound of claim 1 or 2, wherein Lig is selected from the group consisting of an anti-TROP2 antibody, an anti-EGRF antibody, and an anti-HER2 antibody.

4. The compound of any one of claims 1-3, wherein s is 1 or 8.


5. The compound of any one of claims 1-4, wherein the compound is selected from the group consisting of:




,








,





,





,



,

,

,

,

,







,



,



,



,



,



,

,

,

,

,


,




,



, and


;

or a pharmaceutically acceptable salt or stereoisomer thereof,





wherein Lig is selected from the group consisting of an anti-TROP2 antibody, an anti-EGRF antibody, and an anti-HER2 antibody.

6. A compound represented by Formula II:


 (II);











or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:


Y is hydrogen or -C_{1-3}alkyl; and

R is selected from the group consisting of: , , , , and .

7. The compound of claim 6, wherein the compound is selected from the group consisting of:


.


,

,

,

,

,

,

,

,

,

, and


;


or a pharmaceutically acceptable salt thereof.


8. A compound represented by Formula IIIA:



(IIIA);


or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:


L is selected from the group consisting of:



,



,


,


,



,


, and


;

wherein * denotes the point of attachment to R;


R is selected from the group consisting of:














wherein ** denotes the point of attachment to L; and

s is 0, 1, 2, 3, 4, 5, 6, 7, or 8.

9. The compound of claim 8, wherein R is selected from the group consisting of:






,

,

,


,

,

,

,

,

,

,

, and

;

wherein ** denotes the point of attachment to L.


10. The compound of claim 8 or 9, wherein s is 1 or 8.

11. The compound of any one of claims 8-10, wherein the compound is selected from the group consisting of:



,

,




,




,




,





,





,



,



,



,



,



,


,



,


,


,


,

and


.

12. A pharmaceutical composition comprising the compound of any one of claims 1-7, and a pharmaceutically acceptable excipient.

13. Use of the compound of any one of claims 1-7, in the manufacture of a medicament for treating a cancer in a patient in need thereof.

14. The use of claim 13, wherein the cancer is selected from the group consisting of lung cancer, kidney cancer, urothelial cancer, colorectal cancer, prostate cancer, glioblastoma multiforme, ovarian cancer, pancreatic cancer, breast cancer, melanoma, liver cancer, bladder cancer, stomach cancer, and esophageal cancer.